Trial Profile
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Sirolimus (Primary) ; Cobalamin; Dexamethasone; Folic acid
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2019 Status changed from completed to discontinued.
- 15 Nov 2019 Status changed from completed to discontinued.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.